459 related articles for article (PubMed ID: 34493492)
21. B and T cell response to SARS-CoV-2 vaccination in health care professionals with and without previous COVID-19.
Zollner A; Watschinger C; Rössler A; Farcet MR; Penner A; Böhm V; Kiechl SJ; Stampfel G; Hintenberger R; Tilg H; Koch R; Antlanger M; Kreil TR; Kimpel J; Moschen AR
EBioMedicine; 2021 Aug; 70():103539. PubMed ID: 34391087
[TBL] [Abstract][Full Text] [Related]
22. Impact of Kidney Transplantation on Humoral Immunity Against SARS-CoV-2: A Case Series From Belgium.
Fernandes G; Devresse A; Scohy A; Yombi JC; Belkhir L; De Greef J; De Meyer M; Mourad M; Darius T; Buemi A; Kabamba B; Goffin E; Kanaan N
Transplantation; 2021 Nov; 105(11):e257-e258. PubMed ID: 34347716
[No Abstract] [Full Text] [Related]
23. Strong humoral immune responses against SARS-CoV-2 Spike after BNT162b2 mRNA vaccination with a 16-week interval between doses.
Tauzin A; Gong SY; Beaudoin-Bussières G; Vézina D; Gasser R; Nault L; Marchitto L; Benlarbi M; Chatterjee D; Nayrac M; Laumaea A; Prévost J; Boutin M; Sannier G; Nicolas A; Bourassa C; Gendron-Lepage G; Medjahed H; Goyette G; Bo Y; Perreault J; Gokool L; Morrisseau C; Arlotto P; Bazin R; Dubé M; De Serres G; Brousseau N; Richard J; Rovito R; Côté M; Tremblay C; Marchetti GC; Duerr R; Martel-Laferrière V; Kaufmann DE; Finzi A
Cell Host Microbe; 2022 Jan; 30(1):97-109.e5. PubMed ID: 34953513
[TBL] [Abstract][Full Text] [Related]
24. Kinetics and biological characteristics of humoral response developing after SARS-CoV-2 infection: implications for vaccination.
Lippi G; Sciacovelli L; Trenti T; Plebani M;
Clin Chem Lab Med; 2021 Jul; 59(8):1333-1335. PubMed ID: 33578505
[No Abstract] [Full Text] [Related]
25. Antibody, not Cellular, Immune Responses to SARS-CoV-2 Vaccination Outperform Infection in Inflammatory Bowel Disease Patients.
González Cueto E; Edmans M; Wellens J; Cadwell K; Thompson C; Satsangi J; Wong SY;
Inflamm Bowel Dis; 2024 May; 30(5):859-862. PubMed ID: 37935466
[No Abstract] [Full Text] [Related]
26. Immune response to three doses of mRNA SARS-CoV-2 vaccines in CD19-targeted chimeric antigen receptor T cell immunotherapy recipients.
Sesques P; Bachy E; Ferrant E; Safar V; Gossez M; Morfin-Sherpa F; Venet F; Ader F
Cancer Cell; 2022 Mar; 40(3):236-237. PubMed ID: 35093212
[No Abstract] [Full Text] [Related]
27. Humoral and cellular response of two different vaccines against SARS-CoV-2 in a group of healthcare workers: Comment.
Daungsupawong H; Wiwanitkit V
J Immunol Methods; 2024 Jun; 529():113671. PubMed ID: 38593868
[No Abstract] [Full Text] [Related]
28. Cellular and Humoral Immune Responses After 3 Doses of BNT162b2 mRNA SARS-CoV-2 Vaccine in Kidney Transplant.
Stumpf J; Tonnus W; Paliege A; Rettig R; Steglich A; Gembardt F; Kessel F; Kröger H; Arndt P; Sradnick J; Frank K; Tonn T; Hugo C
Transplantation; 2021 Nov; 105(11):e267-e269. PubMed ID: 34342963
[TBL] [Abstract][Full Text] [Related]
29. Absence of Humoral Response After Two-Dose SARS-CoV-2 Messenger RNA Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: A Case Series.
Connolly CM; Boyarsky BJ; Ruddy JA; Werbel WA; Christopher-Stine L; Garonzik-Wang JM; Segev DL; Paik JJ
Ann Intern Med; 2021 Sep; 174(9):1332-1334. PubMed ID: 34029488
[No Abstract] [Full Text] [Related]
30. Antibody responses after SARS-CoV-2 vaccination in patients with lymphoma.
Lim SH; Campbell N; Johnson M; Joseph-Pietras D; Collins GP; O'Callaghan A; Fox CP; Ahearne M; Johnson PWM; Goldblatt D; Davies AJ
Lancet Haematol; 2021 Aug; 8(8):e542-e544. PubMed ID: 34224667
[No Abstract] [Full Text] [Related]
31. Robust and durable serological response following pediatric SARS-CoV-2 infection.
Renk H; Dulovic A; Seidel A; Becker M; Fabricius D; Zernickel M; Junker D; Groß R; Müller J; Hilger A; Bode SFN; Fritsch L; Frieh P; Haddad A; Görne T; Remppis J; Ganzemueller T; Dietz A; Huzly D; Hengel H; Kaier K; Weber S; Jacobsen EM; Kaiser PD; Traenkle B; Rothbauer U; Stich M; Tönshoff B; Hoffmann GF; Müller B; Ludwig C; Jahrsdörfer B; Schrezenmeier H; Peter A; Hörber S; Iftner T; Münch J; Stamminger T; Groß HJ; Wolkewitz M; Engel C; Liu W; Rizzi M; Hahn BH; Henneke P; Franz AR; Debatin KM; Schneiderhan-Marra N; Janda A; Elling R
Nat Commun; 2022 Jan; 13(1):128. PubMed ID: 35013206
[TBL] [Abstract][Full Text] [Related]
32. Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial.
Wu S; Huang J; Zhang Z; Wu J; Zhang J; Hu H; Zhu T; Zhang J; Luo L; Fan P; Wang B; Chen C; Chen Y; Song X; Wang Y; Si W; Sun T; Wang X; Hou L; Chen W
Lancet Infect Dis; 2021 Dec; 21(12):1654-1664. PubMed ID: 34324836
[TBL] [Abstract][Full Text] [Related]
33. Antibody response to SARS-CoV-2 vaccination is extremely vivacious in subjects with previous SARS-CoV-2 infection.
Callegaro A; Borleri D; Farina C; Napolitano G; Valenti D; Rizzi M; Maggiolo F
J Med Virol; 2021 Jul; 93(7):4612-4615. PubMed ID: 33788281
[TBL] [Abstract][Full Text] [Related]
34. Long-Term Humoral Immune Response against SARS-CoV-2 after Natural Infection and Subsequent Vaccination According to WHO International Binding Antibody Units (BAU/mL).
Ruetalo N; Flehmig B; Schindler M; Pridzun L; Haage A; Reichenbächer M; Kirchner T; Kirchner T; Klingel K; Ranke MB; Normann A
Viruses; 2021 Nov; 13(12):. PubMed ID: 34960605
[TBL] [Abstract][Full Text] [Related]
35. The mRNA-1273 Vaccine Induces Cross-Variant Antibody Responses to SARS-CoV-2 With Distinct Profiles in Individuals With or Without Pre-Existing Immunity.
Tejedor Vaquero S; de Campos-Mata L; Ramada JM; Díaz P; Navarro-Barriuso J; Ribas-Llaurado C; Rodrigo Melero N; Carolis C; Cerutti A; Gimeno R; Magri G
Front Immunol; 2021; 12():737083. PubMed ID: 34539673
[TBL] [Abstract][Full Text] [Related]
36. Comprehensive assessment of humoral response after Pfizer BNT162b2 mRNA Covid-19 vaccination: a three-case series.
Danese E; Montagnana M; Salvagno GL; Peserico D; Pighi L; De Nitto S; Henry BM; Porru S; Lippi G
Clin Chem Lab Med; 2021 Aug; 59(9):1585-1591. PubMed ID: 33838087
[TBL] [Abstract][Full Text] [Related]
37. SARS-CoV-2 Messenger RNA Vaccine Immunogenicity in Solid Organ Transplant Recipients With Prior COVID-19.
Boyarsky BJ; Barbur I; Chiang TP; Ou MT; Greenberg RS; Teles AT; Krach MR; López JI; Garonzik-Wang JM; Avery RK; Massie AB; Segev DL; Werbel WA
Transplantation; 2021 Nov; 105(11):e270-e271. PubMed ID: 34284420
[No Abstract] [Full Text] [Related]
38. Characterization of SARS-CoV-2-specific humoral immunity and its potential applications and therapeutic prospects.
Zheng J; Deng Y; Zhao Z; Mao B; Lu M; Lin Y; Huang A
Cell Mol Immunol; 2022 Feb; 19(2):150-157. PubMed ID: 34645940
[TBL] [Abstract][Full Text] [Related]
39. Previous Infection Combined with Vaccination Produces Neutralizing Antibodies with Potency against SARS-CoV-2 Variants.
Ibarrondo FJ; Hofmann C; Ali A; Ayoub P; Kohn DB; Yang OO
mBio; 2021 Dec; 12(6):e0265621. PubMed ID: 34872349
[TBL] [Abstract][Full Text] [Related]
40. Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study.
Sauré D; O'Ryan M; Torres JP; Zuniga M; Santelices E; Basso LJ
Lancet Infect Dis; 2022 Jan; 22(1):56-63. PubMed ID: 34509185
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]